To assess the ability of new compounds to modulate EGFR expression and phosphorylation, we used the triple-negative breast cancer cell line MDA-MB-468, in which the receptor protein is overexpressed compared with the low expression of its counterpart ErbB2 [30]. Here, ERBB2 is linked to triple-negative breast carcinoma.